2019 GU Symposium: Tivozanib Versus Sorafenib in Advanced Renal Cell Carcinoma
Posted: Friday, March 1, 2019
A study conducted by Brian I. Rini, MD, of the Cleveland Clinic, and colleagues suggests patients with metastatic renal cell carcinoma who were treated with the VEGF tyrosine kinase inhibitor tivozanib experienced an improvement in median progression-free survival compared with sorafenib. The TIVO-3 trial, which was carried out to verify the findings from the TIVO-1 trial, was presented at the 2019 Genitourinary Cancers Symposium in San Francisco (Abstract 541).
The study featured 350 patients with metastatic renal cell carcinoma for whom 2 or 3 prior treatments were unsuccessful. Patients were stratified by independent data monitoring committee risk category and type of prior treatment. The therapies included either two tyrosine kinase inhibitors, a tyrosine kinase inhibitor plus a checkpoint inhibitor, or a tyrosine kinase inhibitor plus another treatment. Finally, the patients were randomly assigned to receive either tivozanib or sorafenib.
The median progression-free survival with tivozanib was 5.6 months, compared with 3.9 months with sorafenib. The progression-free survival rate for 2 years was 18% for tivozanib compared with 5% for sorafenib. The overall response rate was 18% for tivozanib versus 8% for sorafenib. Patients receiving tivozanib had a lower rate of grade 3 treatment-related adverse events (44%) than did those receiving sorafenib (55%).
Overall survival favored sorafenib in the TIVO-1 trial; the investigators speculated that was likely due to an imbalanced crossover to active treatments. An interim analysis of overall survival in TIVO-3 also showed no benefit with tivozanib, but a definitive analysis of more mature survival results is planned for later in 2019.
Disclosure: The study authors’ disclosure information may be found at coi.asco.org.